VTVT vTv Therapeutics Inc.: institutional ownership and insider trading
46 funds reported holding $63.8M of vTv Therapeutics Inc. in their latest 13F filings; in Q2 2026 funds net bought $4.51M, with 17 new positions and 6 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $36.8M and net income of −$4.76M.
VTVT revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$13.1M
- Quarter ended Mar 31, 2026: revenue $36.8M, net income $24.1M
- Quarter ended Dec 31, 2025: revenue $0, net income −$7.14M
- Quarter ended Sep 30, 2025: revenue $0, net income −$8.70M
Famous investors holding VTVT
- Izzy Englander (Millennium Management): $10.2M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $657K, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $432K, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $222K, 0.0% of the portfolio
Largest institutional holders of VTVT
- Samsara BioCapital, LLC — $11.2M
- MILLENNIUM MANAGEMENT LLC — $10.2M
- FMR LLC — $9.80M
- Siren, L.L.C. — $6.14M
- BAKER BROS. ADVISORS LP — $5.58M
- VANGUARD CAPITAL MANAGEMENT LLC — $3.56M
- VANGUARD GROUP INC — $3.34M
- Trails Edge Capital Partners, LP — $3.21M
- Aisling Capital Management LP — $1.88M
- MARSHALL WACE, LLP — $1.49M
Recent VTVT insider trades
- Nov 18, 2024: Sekhri Paul J bought 5,000 shares ($83.8K)
5%+ owners
- Millennium Management LLC: 8.7% (Schedule 13G/A, filed Oct 8, 2026)